A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

A Isomorphic Labs, a drug discovery company driven by artificial intelligence (IA) and part of the A (holding of Google), is ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials. Isomorphic Labs, the ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

The global Phase 2 NEULARK clinical trial (NCT06680830) is a randomized, double-blind, placebo-controlled study in people with early-stage, LRRK2-driven PD.

The trial findings indicated that once-monthly maridebart cafraglutide caused a 12.3% to 16.2% reduction in mean body weight among participants with obesity following 52 weeks of treatment.

In a fitting twist for a company called Hims & Hers, the latest drama in the weight-loss drug world has become a classic “he said, she said” tale of alleged corporate misdeeds. On one side is Novo ...

Brown become the first patient to enroll in the trial, which now has signed on more than 1,700 people and is designed to run for another four years. If it proves that some people can manage their ...